Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy

• Status: Completed
• Trial end date: 2016-10-17
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy of pioglitazone 30 mg on glycemic control when used in participants with inadequately controlled type 2 diabetes mellitus treated with stable combinations of metformin and sulfonylurea.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Takeda
• Treatments: Metformin; Pioglitazone

Criteria

Inclusion Criteria

Participants meeting the following criteria will be considered for inclusion in the study:

1. Institutional Review Board (IRB)-approved written informed consent form (ICF) must be obtained from the participant or legally authorized representative prior to any trial related procedure (including withdrawal of prohibited medication, if applicable).

2. Participants with a history of clinical diagnosis of established type 2 diabetes mellitus defined by the American Diabetes Association (ADA) criteria 2012.

3. Male or female between 18 and 80 years of age.

4. Participants with stable triple oral therapy of metformin + sulfonylurea + pioglitazone (ACTOS) 15 mg or ACTOSMET(Pioglitazone 15mg/Metformin 850mg) and sulfonylurea for at least 12 weeks at the screening visit.

5. Participants with glycosylated hemoglobin (HbA1c) ≥7.0% at the screening visit.

6. Participants with C-peptide ≥1.0 ng/mL at the screening visit.

7. Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from screening throughout the duration of the study, up to 30 days after the last dose of the study medication.

Exclusion Criteria

Participants meeting any of the following criteria will be excluded from enrollment:

1. Participants with type 1 diabetes mellitus or secondary forms of diabetes.

2. Participants who have been treated with insulin for ≥7 days within 3 months prior to the screening visit.

3. Participants with a history of bladder cancer or participants with active bladder cancer.

4. Participants with a history of acute diabetic complications such as diabetic ketoacidosis.

5. Participants with a history of acute or chronic metabolic acidosis, including diabetic ketoacidosis.

6. Participants with unstable or rapidly progressive diabetic retinopathy, nephropathy (estimated glomerular filtration rate [eGFR] <60mL/min/1.73m2).

7. Participants with cardiac insufficiency (e.g., a myocardial infarction, a coronary angioplasty or bypass graft, unstable angina, transient ischemic attacks, or a documented cerebrovascular accident within 6 months prior to the screening visit).

8. Participants with cardiac failure or history of cardiac failure (New York Heart Association [NYHA] Stages 3 to 4).

9. Participants with a serum alanine transaminase (ALT) level ≥2.5 times the upper limit of normal (ULN), active liver disease, or jaundice.

10. Participants taking concomitant gemfibrozil or other strong cytochrome P450 (CYP)2C8 inhibitors.

11. Participants with a history of recurrent or severe hypoglycemia.

12. Participants with a history of any hemoglobinopathy (such as hemolytic anemias or sickle cell disease) that may affect determination of HbA1c.

13. Participants with uninvestigated microscopic hematuria

14. Participants with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption, since the study drug contains lactose.

15. Participants with any other condition judged by the Investigator as unsuitable for the study.

16. Participants who have used any investigational or experimental drugs or devices within 60 days of the screening visit.

17. Lactating or pregnant female. A positive pregnancy test before the first administration of investigational medicinal product (IMP) or breastfeeding.

18. Male participants planning to father during clinical trial conduct or within 3 months after the last planned dose of the IMP.

19. Participants were previously enrolled into the current clinical trial.

20. The participants participated in the active treatment phase of another clinical trial where a persisting pharmacodynamic effect of the IMP of that clinical trial cannot be excluded.

21. Participants are considered unable or unwilling to co-operate adequately, i.e., to follow clinical trial procedures after Investigator has adequately instructed (e.g., language difficulties, etc.) or participants are anticipated not to be available for scheduled clinical trial visits/procedures.